Tractor Supply Company

▲ Bull Case

• ◆Comp recovery of +3–4% driven by post-COVID rural lifestyle destocking normalization, combined with Allivet revenue ramp ($300–500M in 3–5 years at 20%+ contribution margins) and buyback resumption, drives FY2027 EPS to $2.35 at 27x P/E — implying a price of ~$63 and a total return of +62.5%.
• ◆The rural category captain moat is wide and self-reinforcing: 2,602 stores in markets with no direct competitor within 20–30 miles create a quasi-monopoly in each micromarket, while the 37M Neighbor's Club members generate a proprietary data flywheel for personalized offers and repeat-purchase behavior that no competitor can quickly replicate.
• ◆Life Out Here 2030 adds ~600 net new stores (23% unit growth) in rural greenfield markets with low rents, minimal cannibalization risk, and proven unit economics — each new store matures to ~$6–7M annual revenue — extending TSCO's long-duration compounding runway well beyond FY2030.

▼ Bear Case

• ◆EPS stagnation proves structural rather than cyclical: sustained SG&A deleverage from wage inflation and elevated CapEx, combined with continued post-COVID rural lifestyle hangover, keeps FY2026 EPS near $2.12 at a 15x trough P/E — implying a price of ~$32 and a total return of −15.2%.
• ◆Amazon accelerates rural last-mile penetration and Chewy Rx/PetMeds/Amazon Pharmacy prove too entrenched for Allivet to gain meaningful share, forcing a material impairment charge (>$50M) and a strategic reversal that signals a capital allocation error and reduces management credibility.
• ◆In a severe scenario (5% probability), rural consumer financial stress, competitive disruption, and Allivet writedown converge — FY2026 EPS falls to $1.70 at 12x P/E — implying a price of ~$20 and a total return of −47.6%.

“The central debate on TSCO is whether three years of EPS stagnation (~$2.02–2.06) represents a cyclical post-COVID normalization that is now ending, or a structural derating of the rural lifestyle category's growth algorithm. Bulls point to the +1.2% comp in FY2025 as the first evidence of normalization after two near-zero comp years, and model a re-rating to 23–27x P/E once EPS growth resumes. Bears argue that the fixed-cost structure is not sufficiently flexible to generate operating leverage at low-single-digit comps, that Allivet is an expensive bet in a competitive pet Rx market TSCO has no experience in, and that 11 analyst estimate cuts after the Q1 FY2026 miss suggest the recovery timeline keeps slipping. Consensus analyst median price target of ~$48–50 (post-split) implies the market has already partially priced in the base-case recovery, leaving limited reward for new investors at current levels. A secondary debate concerns Life Out Here 2030 unit economics — whether construction cost inflation has raised the hurdle rate enough to reduce the incremental ROIC on new stores materially below historical averages.”

• ◆Q2 FY2026 earnings (~late July/August 2026): spring/summer seasonal comp results — most important near-term inflection point for the thesis
• ◆Comp sales acceleration to +3–4% range, signaling the post-COVID rural lifestyle destocking is fully resolved and the growth algorithm is intact
• ◆Allivet KPI disclosure: any management disclosure of revenue run-rate, active customer counts, or prescription fill volumes that demonstrates traction in the $15B pet Rx market
• ◆CapEx normalization signal: FY2026–2027 CapEx guidance reduction toward $700–780M, confirming the Life Out Here 2030 investment peak has passed and FCF inflection is imminent
• ◆Buyback resumption above $300M/year, demonstrating management confidence in the stock and providing per-share EPS accretion support
• ◆Life Out Here 2030 site pipeline update confirming 80–90 net new store openings on track with favorable unit economics

• ◆Comparable store sales decline below −2% for 3 consecutive quarters (Kill Switch #1): signals structural rather than cyclical EPS stagnation; triggers 30% position reduction
• ◆Operating margin falls below 8.5% for 2 consecutive quarters (Kill Switch #2): indicates SG&A fixed-cost structure cannot absorb comp weakness; triggers 25% position reduction
• ◆Amazon and other e-commerce players accelerate rural last-mile penetration, eroding the geographic switching-cost moat that underpins the entire investment thesis
• ◆Allivet generates a material impairment charge (>$50M) or management announces restructuring/divestiture (Kill Switch #4): signals capital allocation error; triggers 20% position reduction
• ◆Life Out Here 2030 store opening pace revised below 70 net new stores annually (Kill Switch #3): signals management confidence in unit economics has declined; triggers 15% position reduction
• ◆Share repurchase program remains below $300M/year for 3 consecutive quarters (Kill Switch #5): signals CapEx and operating uncertainty have crowded out capital return; triggers 10% position reduction
• ◆Construction cost inflation raises CapEx per new store above historical averages, reducing incremental ROIC below hurdle rate and forcing a strategic revision of the 3,200-store target
• ◆Rural consumer financial stress from sustained elevated interest rates or farm income decline reduces discretionary spending even within the rural lifestyle category